Linked from

The 74 pages that link to Dopamine, each with the reason it gives.

• ParkinsonismRelated: Reduced dopaminergic signaling contributes to bradykinesia and often responds to replacement therapy.

• Tourette syndromeRelated: Dopaminergic signaling is one target of treatments that reduce severe tics.

• VareniclineRelated: Varenicline alters nicotine-linked dopamine signaling in reward pathways.

• CatecholRelated: Dopamine is a familiar biological molecule built around catechol functionality.

• ChoreaRelated: Dopamine-modifying medicines can either reduce chorea or trigger it, depending on the condition and treatment.

• HaloperidolNarrower topic: Haloperidol’s principal target acts by responding to this neurotransmitter.

• PhenethylamineBroader topic: Dopamine is a biologically central, hydroxylated member of the broader phenethylamine family.

• ApomorphineNarrower topic: Apomorphine mimics dopamine at receptors rather than replacing the missing neurons that produce it.

• AtomoxetineRelated: In the prefrontal cortex, norepinephrine transporter blockade also reduces dopamine clearance.

• EndorphinsCompared with: Dopamine shapes reward through a signaling system distinct from opioid peptide receptors.

• PleasureRelated: Dopamine contributes more to motivational pursuit and learning than to pleasure alone.

• ProlactinomaRelated: Reduced dopamine signaling can raise prolactin, while dopamine-mimicking drugs often shrink these tumors.

• SelegilineRelated: Slowing dopamine breakdown helps compensate for dopamine loss in Parkinson’s disease.

• CatalepsyRelated: Dopamine-blocking drugs can induce cataleptic states in experimental animals.

• Delusional parasitosisRelated: Dopamine-related mechanisms are proposed, but they do not fully explain the condition.

• DextroamphetamineNarrower topic: Dopamine signaling helps explain both therapeutic effects and misuse potential.

• PramipexoleRelated: Pramipexole mimics dopamine’s action when signaling is deficient.

• ReserpineBroader topic: Dopamine is among the transmitters depleted when reserpine blocks vesicular storage.

• AgomelatineRelated: 5-HT2C blockade can increase dopamine release in frontal brain regions.

• CathinoneRelated: Changes in dopamine signaling contribute to cathinone’s reinforcing and activating effects.

• Coolidge effectBroader topic: Dopamine signaling is implicated in motivated responses to novel rewards.

• HyperactivityRelated: Dopamine systems are implicated in ADHD, but hyperactivity is not reducible to a single chemical cause.

• HyperprolactinaemiaRelated: Reduced dopamine signaling removes the main restraint on prolactin release.

• NeuroeconomicsRelated: Dopamine signals contribute to learning from outcomes and updating expected values.